Table 3.
Summary of interview data per informant group
| AXES | Informant group | Coded responses |
|---|---|---|
| AXIS I | Policy makers & Gastroenterology Association informant | • Other competing priorities to get policy attention & budget allocation |
| Raising awareness, promoting partnerships and mobilizing resources | • No implementing & donor agencies | |
| • No organizing body | ||
| • Minimal media awareness initiatives | ||
| Patients | • Traditional beliefs | |
| • No awareness about the disease & transmission | ||
| • Awareness obtained via incidental diagnosis of oneself or close relative | ||
| AXIS II | Policy makers & Gastroenterology Association informant | • No policy & strategy for prevention, care & treatment |
| Evidence-based policy & data for action | • No current national survey on both hepatitis B & C | |
| • No hepatitis surveillance system | ||
| • No antivirals for hepatitis treatment registered on essential drug list | ||
| AXIS III | Policymakers | • Hepatitis B vaccine as pentavalent vaccine in Expanded Program on Immunization(EPI) |
| Prevention of transmission | • 24-h-Birth-dose of hepatitis B vaccine not available | |
| • No Adult Hepatitis B catch-up vaccine administration policy | ||
| • No Hepatitis specific health promotion or health education strategy | ||
| • HIV prevention activity indirectly helps in control of viral hepatitis | ||
| Laboratory technologists | • Standard of Practice to screen HIV, Hepatitis, & C, and Syphilis in blood banks | |
| • Hepatitis screening only in private institutions upon request | ||
| AXIS IV | Healthcare professionals | • Hepatitis screening only in private institutions upon request |
| Screening, care & treatment | • No organized treatment facility in the country | |
| • Smuggled hepatitis treatment drugs are not affordable | ||
| • Lab investigation for treatment follow-up done abroad through agents, and is neither affordable nor accessible to the majority | ||
| • Patients neglected & discriminated | ||
| • Getting treatment is a human right issue | ||
| Pharmacists | • Antivirals for hepatitis treatment not available on market | |
| • Antivirals for hepatitis treatment not registered on essential drug list | ||
| Drug suppliers | • No legal support to import antivirals for hepatitis and HIV | |
| • Case-based drug import by prescription is very expensive | ||
| • No awareness as a major health problem | ||
| Clients | • No awareness about hepatitis screening | |
| • Prescribed drugs not available on market | ||
| • Smuggled hepatitis treatment drugs are not affordable | ||
| • Feeling of discrimination | ||
| Client case stories | • four case stories narrated |